Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CD19-CAR-T cells (Bioceltech Therapeutics)
- Development stage
- Unknown
- Lead developer
- Bioceltech Therapeutics
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
CD19-CAR-T cells (Bioceltech Therapeutics) is an investigational chimeric antigen receptor (CAR) T-cell therapy developed for the treatment of relapsed or refractory B-cell acute lymphoblastic leukemia (R/R B-ALL). The therapy involves genetically modifying either autologous (patient-derived) or HLA-haploidentical allogeneic (donor-derived) T cells using a lentiviral vector to express a CAR specific for the CD19 antigen, a surface protein widely expressed on B-lineage cells. The CAR construct incorporates a 4-1BB (CD137) costimulatory domain and a CD3-zeta signaling domain to enhance T-cell activation, expansion, and persistence upon binding to CD19-positive tumor cells. This immunotherapy was evaluated in a Phase I clinical trial in China to assess safety and efficacy in patients who have failed standard treatments.
- Other names
- CD19-targeted chimeric antigen receptor T-cell therapyCD-19-targeted chimeric antigen receptor T-cell therapyCD 19-targeted chimeric antigen receptor T-cell therapyAutologous CD19-CAR-T cellsDonor-derived allogeneic CD19-CAR-T cells
02
Targets
Beyond the preview
Go deeper on CD19-CAR-T cells (Bioceltech Therapeutics).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CD19-CAR-T cells (Bioceltech Therapeutics).